A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 341 participants.

Also called NCT01256411

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 341 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01256411
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Japan, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01256411. Allocation not applicable; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2015-10-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Amlodipine
Intervention (Drug)
Hydrochlorothiazide (HCTZ)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01256411
Content hash
55aa794582f3b5da60c107581763fe3d623ec88b62b2544ad8ff2898123aacb4